Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2009

View Archived Issues

Kyowa Hakko Kirin reports results from quarter ended September 30, 2009

Universidad de Oviedo describes oviedomycin derivatives for cancer therapy

Novel anxiolytic compounds identified by Forskarpatent

Eisai launches oral jelly formulation of Aricept for Alzheimer's disease

Atorvastatin evaluated in patients with post-stroke dementia

Biomarker identified for bevacizumab efficacy in colorectal cancer

Gene product plasmid AMEP to enter phase I metastatic melanoma investigation

Safety and immunogenicity data reported for Synflorix pneumococcal vaccine

Latin American studies show potential of hexavalent Hexaxim vaccine

Improved cognitive function seen in elderly subjects given Ropren

Biovitrum expands Kineret license to include orphan indications

Data collection complete in Biofrontera's final trial of BF-200 ALA for actinic keratosis

Pfizer and Protalix to develop and commercialize taliglucerase alfa for Gaucher's disease

Encouraging phase II trial results reported for talactoferrin in sepsis

Bayer Schering Pharma and Micromet to collaborate on new BiTE antibody cancer therapy

AnGes and FDA agree on SPA for phase III trial of Collategene in ischemia

Stallergenes obtains European marketing authorization for Oralair

Bayer Schering's Betaferon approved in China to treat multiple sclerosis

Clarient is granted exclusive right to commercialize MUC1* diagnostic cancer test

FDA approves Avioq HIV-1 microelisa system for detection of antibodies against HIV-1

Merck Serono to expand research and development in China

NexMed to acquire Bio-Quant

FDA clears ProParaflu+ parainfluenza assay for marketing

Novartis claims MMP inhibitors for the treatment of Alport syndrome

Glucocorticoid receptor modulators disclosed by Ligand as anti-inflammatory agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...